Last checked at 16 Jan 2024 17:17
FTSE 100 hits one-month low, precious miners biggest drag
FTSE 100 down 0.5%, FTSE 250 flat
*Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades18,291
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
11,988.00
Bid:
12,016.00
Ask:
12,020.00
Change:
-38.00 (-0.32%)
Spread:
4.00 (0.033%)
Open:
12,070.00
High:
12,144.00
Low:
11,882.00
Prev. Close:
12,026.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.AstraZeneca's Imfinzi fails to reach endpoint in difficult trial
Fri, 07th Dec 2018 07:24
(Sharecast News) - AstraZeneca and its global biologics research and development arm MedImmune announced overall survival results for the Phase III EAGLE trial of Imfinzi (durvalumab) on Friday.The FTSE 100 pharmaceutical behemoth described EAGLE as a randomised, open-label, multi-centre trial evaluating Imfinzi monotherapy or Imfinzi in combination with tremelimumab - an anti-CTLA4 antibody - compared to standard-of-care chemotherapy, in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who experienced disease progression following platinum-based chemotherapy, regardless of their PD-L1 tumour status.It said Imfinzi monotherapy and the combination of Imfinzi plus tremelimumab did not meet the primary endpoints of improving overall survival compared to standard-of-care chemotherapy in the "hard-to-treat" patients.The safety and tolerability profiles for Imfinzi and the combination with tremelimumab were consistent with previous experience."The prognosis for recurrent or metastatic head and neck squamous cell cancer is very poor and new treatments for this group of cancers are urgently needed," said AstraZeneca's executive vice-president of global medicines development and chief medical officer Sean Bohen."While these results are disappointing, we remain committed to evaluating the potential of Imfinzi and other innovative medicines for patients with head and neck cancer."We look forward to seeing the results of the Phase III KESTREL trial of Imfinzi and tremelimumab in patients who have not received prior chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma in the first half of 2019."AstraZeneca said it would submit the results from the Phase III EAGLE trial for presentation at a forthcoming medical meeting.
More News
16 Jan 2024 16:17
London close: Stocks finish lower as wage growth eases
(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.
Read more16 Jan 2024 11:58
LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth
(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.
Read more16 Jan 2024 09:14
LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:
Read more16 Jan 2024 08:15
UBS downgrades AstraZeneca to 'sell'
(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.
Read more9 Jan 2024 10:50
Novartis in advanced talks to buy Cytokinetics- source
Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.
Read more8 Jan 2024 14:08
Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference
NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.
Read more6 Jan 2024 17:44
Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference
NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.
Read more5 Jan 2024 12:00
Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference
NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.
Read more3 Jan 2024 17:48
London close: Stocks fall amid rising geopolitical concerns
(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.
Read more3 Jan 2024 16:52
LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes
(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.
Read more3 Jan 2024 11:07
Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'
(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.
Read more3 Jan 2024 10:16
IN BRIEF: Nuformix narrows annual loss as develops drug assets
Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.
Read more3 Jan 2024 10:12
AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.
Read more3 Jan 2024 09:23
LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:
Read more